Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Current treatments for Hepatitis C virus (HCV) have severe side effects and are very expensive. There is a need to explore effective natural therapies against HCV that are less toxic and more cost-effective.

37 chronic HCV infected patients were randomized into two groups and treated with PEG interferon plus ribavirin for the first group or Biobran, an arabinoxylan from rice bran (1 g/day) for the second group. Viremia level, liver enzymes, γ-interferon (IFN-γ) levels in serum, and toxicity were checked before and three months after treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Collaborators: Daiwa Pharmaceutical Corporation Co, Ltd, Tokyo 154-0024 Japan; University of California, Los Angeles
• Treatments: Immunologic Factors; Interferon-alpha; Interferons; Ribavirin

Criteria

Inclusion Criteria:

• Patients diagnosed with chronic HCV infection and chronic active liver diseases.

Exclusion Criteria:

• Patients diagnosed with chronic HBV , HIV infection , autoimmune disorders , any heart diseases , any kidney diseases or any blood disease , any neoplastic disorders.

• Pregnant or lactating ladies , and drug abusers will be excluded.